Conformal Radiotherapy of Clinically Localized Prostate Cancer: Analysis of Rectal and Urinary Toxicity and Correlation with Dose-Volume Parameters

Quaglia A. , Parody S. , Grosclaude P. , Martinez-Garcia C. , Coebergh J.W. , Vercelli M. : Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe: an analysis of differential trends in incidence and mortality in France, Italy and Spain. Eur J Cancer, 39: 654–665, 2003.

Pollack A. , Zagars G.K. , Starkschall G. , Antolak J.A. , Lee J.J. , Huang E. , von Eschenbach A.C. , Kuban D.A. , Rosen I. : Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. IntJ Radiat Oncol Biol Phys, 53: 1097–1105, 2002.

Magrini S.M. , Bertoni F. , Vavassori V. , Villa S. , Cagna E. , Maranzano E. , Pertici M. , Pradella R. , Spediacci M.A. , Chiavacci A. , Ambrosi E. , Livi L. , Magli A. , Bellavita R. , Bossi A. , Biti G. : Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980–1998). Int J Radiat Oncol Biol Phys, 52: 1310–19, 2002.

Hanks G.E. , Hanlon A.L. , Schultheiss T.E. , Pinover W.H. , Movsas B. , Epstein B.E. , Hunt M.A. : Dose escalation with 3D conformal treatment: five years outcome, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys, 41: 501–510, 1998.

Zietman A.L. , Coen J.J. , Dallow K.C. , Shipley W.U. : The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys, 32: 287–292, 1995.

Morris D. , Emami B. , Mauch P.M. , Konski A.A. , Tao M.L. , Ng A.K. , Klein E.A. , Mohideen N. , Hurwitz M.D. , Fraas B.A. , Roach M 3rd , Gore E.M. , Tepper J.E. : Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys, 62: 3–19, 2005.

Hanks G.E. , Hanlon A.L. , Pinover W.H. , Horwitz E.M. , Price R.A. , Schultheiss T. : Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys, 46: 823–832, 2000.

Zelefsky M.J. , Fuks Z. , Hunt M. , Yamada Y. , Marion C. , Ling C.C. , Amols H. , Venkatraman E.S. , Leibel S.A. : High-dose intensity-modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys, 53: 1111–1116, 2002.

Lawton C.A. , Won M. , Pilepich M.V. , Asbell S.O. , Shipley W.U. , Hanks G.E. , Cox J.D. , Perez C.A. , Sause W.T. , Doggett S.R. : Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys, 21: 935–939, 1991.

Letourneau D. , Wong J.W. , Oldham M. , Gulam M. , Watt L. , Jaffray D.A. , Siewerdsen J.H. , Martinez A.A. : Cone-beam CT-guided radiation therapy: technical implementation. Radiother Oncol, 75: 279–286, 2005.

Peignaux K. , Truc G. , Barillot I. , Ammor A. , Naudy S. , Créhange G. , Maingon P. : Clinical assessment of the use of the Sonarray system for daily prostate localization. Radiother Oncol, 81: 176–178, 2006.

Speight J.L. , Roach M. III : Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol, 25: 987–995, 2007.

Fiorino C. , Sanguineti G. , Cozzarini C. , Fellin G. , Foppiano F. , Menegotti L. , Piazzolla A. , Vavassori V. , Valdagni R. : Rectal dose–volume constraints in high-dose conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys, 57: 953–962, 2003.

Greco C. , Mazzetta C. , Cattani F. , Tosi G. , Castiglioni S. , Fodor A. , Orecchia R. : Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol, 69: 215–222, 2003.

Liu M. , Pickles T. , Berthelet E. , Agranovich A. , Kwan W. , Tyldesley S. , McKenzie M. , Keyes M. , Morris J. , Pai H. : Prostate cohort initiative. urinary incontinence in prostate cancer patients treated with external beam radiotherapy. Radiother Oncol, 74: 197–201, 2005.

Geinitz H. , Zimmermann F.B. , Thamm R. , Erber C. , Müller T. , Keller M. , Busch R. , Molls M. : Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radiother Oncol, 79: 341–347, 2006.

Marzi S. , Arcangeli G. , Saracino B. , Petrongari M.G. , Bruzzaniti V. , Iaccarino G. , Landoni V. , Soriani A. , Benassi M. : Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer. Int J Radiat Oncol Biol Phys, 68: 41–49, 2007.

Vavassori V. , Fiorino C. , Rancati T. , Magli A. , Fellin G. , Baccolini M. , Bianchi C. , Cagna E. , Mauro F.A. , Monti A.F. , Munoz F. , Stasi M. , Franzone P. , Valdagni R. : Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys, 67: 1401–1410, 2007.

Sobin H. , Witteking C. : TNM Classification of Malignant Tumors. UICC, 6th edn, Wiley-Liss, New York, 2002.

National Comprehensive Cancer Network (NCCN) prostate cancer. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 1.2007. Jenkinstown, PA, National Comprehensive Cancer Network, March 2007.

International Commission of Radiation Units and Measurements. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: ICRU, 1993.

International Commission on Radiation Units and Measurements. ICRU Report 62: Prescribing, recording, and reporting photon beam therapy (supplement to ICRU Report 50). Bethesda, MD: ICRU; 1999.

Cox J.D. , Stetz J. , Pajak T.F. : Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31: 1341–1346, 1995.

American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys, 37: 1035–1041, 1997.

Roach M III , Hanks G. , Thames H. , Schellhammer P. , Shipley W. , Sokol G.H. , Sandler H. : Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys, 65: 965–974, 2006.

Dirix P. , Haustermans K. , Junius S. , Withers R. , Oyen R. , Van Poppel H. : The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol, 79: 1–14, 2006.

Bagshaw M.A. : Radiotherapeutic treatment of prostatic carcinoma with pelvic node involvement. Urol Clin North Am, 11: 297–304, 1984.

Asbell S.O. , Krall J.M. , Pipelich M.V. , Baerwald H. , Sause W.T. , Hanks G.E. , Perez C.A. : Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys, 15: 1307–1316, 1988.

Asbell S.O. , Martz K.L. , Pilepich M.V. , Baerwald H. , Sause W.T. , Doggett R.L. , Perez C.A. : Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77-06, a phase III study for T1bN0M0 (A2) and T2N0M0 (B) prostate. Int J Radiat Oncol Biol Phys, 17: 945–951, 1989.

Pilepich M.V. , Krall J.M. , Johnson R.J. , Sause W.T. , Perez C.A. , Zinninger M. , Martz K. : Extended field (periaortic) irradiation in carcinoma of the prostate-analysis of RTOG 75–06. Int J Radiat Oncol Biol Phys, 12: 345–351, 1986.

Roach M III , DeSilvio M. , Lawton C. , Uhl V. , Machtay M. , Seider M.J. , Rotman M. , Jones C. , Asbell S.O. , Valicenti R.K. , Han S. , Thomas C.R. Jr. , Shipley W.S. : A phase III trial comparing whole pelvic versus prostate only radiotherapy and neoadjuvant concurrent versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group (RTOG) 9413. J Clin Oncol, 21: 1904–1911, 2003.

Roach M III , DeSilvio M. , Valicenti R. , Grignon D. , Asbell S.O. , Lawton C. , Thomas C.R. Jr. , Shipley W.U. : Whole-pelvis, “mini-pelvis”, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys, 66: 647–653, 2006.

Lawton C.A. , Desilvio M. , Roach M III , Uhl V. , Kirsch R. , Seider M. , Rotman M. , Jones C. , Asbell S. , Valicenti R. , Hahn S. , Thomas C.R. Jr. : An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys, 69: 646–655, 2007.

Storey M.R. , Pollack A. , Zagars G. , Smith L. , Antolak J. , Rosen I. : Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys, 48: 635–642, 2000.

Vargas C. , Martinez A. , Kestin L.L. , Yan D. , Grills I. , Brabbins D.S. , Lockman D.M. , Liang J. , Gustafson G.S. , Chen P.Y. , Vicini F.A. , Wong J.W. : Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys, 62: 1297–1308, 2005.

Peeters S.T. , Lebesque J.V. , Heemsbergen W.D. , van Putten W.L. , Slot A. , Dielwart M.F. , Koper P.C. : Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 64: 1151–1161, 2006.

Kupelian P.A. , Willoughby T.R. , Reddy C.A. , Klein E.A. , Mahadevan A. : Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys, 68: 1424–1430, 2007.

Kuban D.A. , Tucker S.L. , Dong L. , Starkschall G. , Huang E.H. , Cheung M.R. , Lee A.K. , Pollack A. : Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys, 70: 67–74, 2008.

Valdagni R. , Italia C. , Montanaro P. , Lanceni A. , Lattuada P. , Magnani T. , Fiorino C. , Nahum A. : Is the alpha-beta ratio of prostate cancer really low? A prospective non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiat Oncol, 75: 74–82, 2005.

Skala M. , Rosewall T. , Dawson L. , Divanbeigi L. , Lockwood G. , Thomas C. , Crook J. , Chung P. , Warde P. , Catton C. : Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 68: 690–698, 2007.

Dale W. , Campbell T. , Ignacio L. , Song P. , Kopnick M. , Mamo C. , Ray P. , Vijayakumar S. : Self-assessed health related quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient assessed bother or symptoms. Urology, 53: 359–366, 1999.

Kuban D.A. , Tucker S.L. , Dong L. , Starkschall G. , Huang E.H. , Cheung M.R. , Lee A.K. , Pollack A. : Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys, 70: 67–74, 2008.

Valdagni R. , Rancati T. , Fiorino C. , Fellin G. , Magli A. , Baccolini M. , Bianchi C. , Cagna E. , Greco C. , Mauro F.A. , Monti A.F. , Munoz F. , Stasi M. , Franzone P. , Vavassori V. : Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys, 71: 1065–1073, 2008.

Peeters S.T. , Heemsbergen W.D. , Koper P.C. , van Putten W.L. , Slot A. , Dielwart M.F. , Bonfrer J.M. , Incrocci L. , Lebesque J.V. : Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol, 24: 1990–1996, 2006.

Fiorino C. , Cozzarini C. , Vavassori V. , Sanguineti G. , Bianchi C. , Cattaneo G.M. , Foppiano F. , Magli A. , Piazzolla A. : Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: Analysis of a large group of patients pooled from three institutions. Radiother Oncol, 64: 1–12, 2002.

Koper P.C. , Jansen P. , van Putten W. , van Os M. , Wijnmaalen A.J. , Lebesque J.V. , Levendag P.C. : Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol, 73: 1–9, 2004.

Stasi M. , Munoz F. , Fiorino C. , Pasquino M. , Baiotto B. , Marini P. , Malinverni G. , Valdagni R. , Gabriele P. : Emptyng the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3DCRT of prostate cancer. Radiother Oncol, 80: 363–370, 2006.

Harsolia A. , Vargas C. , Yan D. , Brabbins D. , Lockman D. , Liang J. , Gustafson G. , Vicini F. , Martinez A. , Kestin L.L. : Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys, 69: 1100–1109, 2007.

Nakamura R.A. , Monti C.R. , Castilho L.N. , Trevisan F.A. , Valim A.C. , Reinato J.A. : Prognostic factors for late urinary toxicity grade 2–3 after conformal radiation therapy on patients with prostate cancer. Int Braz J Urol, 33: 652–661, 2007.

Dearnaley D.P. , Sydes M.R. , Langley R.E. , Graham J.D. , Huddart R.A. , Syndikus I. , Matthews J.H. , Scrase C.D. , Jose C.C. , Logue J. , Stephens R.J. , RT01 Collaborators: The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol, 83: 31–41, 2007.

Moiseenko V. , Liu M. , Kristensen S. , Gelowitz G. , Berthelet E. : Effect of bladder filling on doses to prostate and organs at risk: a treatment planning study. J Appl Clin Med Phys, 12: 55–68, 2006.

Eade T.N. , Hanlon A.L. , Horwitz E.M. , Buyyounouski M.K. , Hanks , Pollack A. : What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys, 68: 682–689, 2007.

Kuban D. , Thames H. , Levy L. , Horwitz E. , Kupelian P. , Martinez A. , Michalski J. , Pisansky T. , Sandler H. , Shipley W. , Zelefsky M. , Zietman A. : Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys, 61: 409–414, 2005.

D'Amico A.V. , Manola J. , Loffredo M. , Renshaw A.A. , Della Croce A. , Kantoff P.W. : 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA, 292: 821–827, 2004.

Bruns F. , Franzki C. , Wegener G. , Karstens J.H. : Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course. Anticancer Res, 27: 1847–1851, 2007.

Thames H. , Kuban D. , Levy L. , Horwitz E.M. , Kupelian P. , Martinez A. , Michalski J. , Pisansky T. , Sandler H. , Shipley W. , Zelefsky M. , Zietman A. : Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys, 57: 929–943, 2003.

Vicini F.A. , Kestin L.L. , Martinez A.A. : The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys, 45: 553–561, 1999.